ArticleFrontiers in oncology2026
Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer.Journal of ovarian research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to describe differences in characteristics and outcomes between patients with platinum sensitive or platinum resistant advanced ovarian cancer in a community oncology setting. Methods: This was a retrospective study of adult patients with Stage III/IV ovarian cancer who received 4+ cycles of a front-line platinum-based regimen between 01/01/2017 and 06/30/2021 (followed until 12/31/2021) within The US Oncology Network. Platinum sensitive or resistant patients were included while refractory patients were excluded. Structured and chart review data were used. Multivariable logistic regression assessed factors associated with platinum sensitivity vs. resistance. Results: A total of 108 platinum sensitive and 34 resistant patient charts were reviewed. In addition to platinum-based chemotherapy, 19% of patients also initiated bevacizumab as part of their front-line regimen. Most patients were White (63%) and diagnosed at Stage IIIC (55%) or IV (33%). ECOG performance status scores were 0/1 for 47% and 2+ for 20% of patients while BRCA mutations were observed among 7.7%. Sensitive vs. resistant patients were younger (p=0.045) and fewer were obese (p=0.011). Stage IV disease (odds ratio [OR]=3.6, p=0.009) was associated with significantly higher odds of platinum resistance after front-line treatment compared to Stage III, while obesity (OR = 2.6, p=0.067) and ECOG 2+ (OR = 2.9, p=0.057) were non-significantly associated with higher odds of resistance. Median overall survival was not reached in sensitive patients, and was 16.7 months in resistant patients. Median progression-free survival in sensitive and resistant patients was 19.6 and 7.9 months, respectively. Discussion: When exploring factors associated with response to front-line platinum-based treatment of ovarian cancer, Stage IV disease was significantly associated with resistance. As platinum resistant patients have poorer survival and fewer treatment options, it is important to further define the biology and appropriate initial management of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.